AAAAAA

   
Results: 1-13 |
Results: 13
INHIBITION OF PLATELET-AGGREGATION AS A SURROGATE MARKER
Authors: NARJES H MULLER TH WEISENBERGER H GUTH B BRICKL R
Citation: H. Narjes et al., INHIBITION OF PLATELET-AGGREGATION AS A SURROGATE MARKER, Journal of clinical pharmacology, 37(1), 1997, pp. 59-64
INHIBITION OF PLATELET-FUNCTION, PK-PD RELATIONSHIP AND TOLERABILITY OF DT-TX-30-SE, A NOVEL COMBINED TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE SYNTHETASE INHIBITOR, IN HEALTHY-VOLUNTEERS/
Authors: NARJES H MULLER TH WEISENBERGER H TANSWELL P DEICHSEL G SU CAPF
Citation: H. Narjes et al., INHIBITION OF PLATELET-FUNCTION, PK-PD RELATIONSHIP AND TOLERABILITY OF DT-TX-30-SE, A NOVEL COMBINED TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE SYNTHETASE INHIBITOR, IN HEALTHY-VOLUNTEERS/, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 64-64
PROFOUND AND SUSTAINED INHIBITION OF PLATELET-AGGREGATION BY FRADAFIBAN, A NONPEPTIDE PLATELET GLYCOPROTEIN IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG, LEFRADAFIBAN, IN MEN/
Authors: MULLER TH WEISENBERGER H BRICKL R NARJES H HIMMELSBACH F KRAUSE J
Citation: Th. Muller et al., PROFOUND AND SUSTAINED INHIBITION OF PLATELET-AGGREGATION BY FRADAFIBAN, A NONPEPTIDE PLATELET GLYCOPROTEIN IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG, LEFRADAFIBAN, IN MEN/, Circulation, 96(4), 1997, pp. 1130-1138
CLINICAL PHARMACOKINETICS OF MELOXICAM
Authors: TURCK D BUSCH U HEINZEL G NARJES H
Citation: D. Turck et al., CLINICAL PHARMACOKINETICS OF MELOXICAM, Arzneimittel-Forschung, 47(3), 1997, pp. 253-258
PHARMACOKINETICS OF MELOXICAM IN PATIENTS WITH HEPATIC CIRRHOSIS IN COMPARISON WITH HEALTHY-VOLUNTEERS
Authors: BUSCH U HEINZEL G NARJES H NEHMIZ G TURCK D KRIMMER J ROSCH W
Citation: U. Busch et al., PHARMACOKINETICS OF MELOXICAM IN PATIENTS WITH HEPATIC CIRRHOSIS IN COMPARISON WITH HEALTHY-VOLUNTEERS, Clinical drug investigation, 11(2), 1996, pp. 97-107
INTERACTION OF MELOXICAM WITH CIMETIDINE, MAALOX, OR ASPIRIN
Authors: BUSCH U HEINZEL G NARJES H NEHMIZ G
Citation: U. Busch et al., INTERACTION OF MELOXICAM WITH CIMETIDINE, MAALOX, OR ASPIRIN, Journal of clinical pharmacology, 36(1), 1996, pp. 79-84
EFFECT OF FOOD ON THE PHARMACOKINETICS OF MELOXICAM AFTER ORAL-ADMINISTRATION
Authors: TURCK D BUSCH U HEINZEL G NARJES H NEHMIZ G
Citation: D. Turck et al., EFFECT OF FOOD ON THE PHARMACOKINETICS OF MELOXICAM AFTER ORAL-ADMINISTRATION, Clinical drug investigation, 9(5), 1995, pp. 270-276
TOLERABILITY AND PLATELET FIBRINOGEN RECEPTOR OCCUPANCY (FRO) AFTER ORAL TREATMENT WITH BIBU-104-XX IN HEALTHY-VOLUNTEERS
Authors: NARJES H WEISENBERGER H MULLER TH DEICHSEL G KRAUSE J
Citation: H. Narjes et al., TOLERABILITY AND PLATELET FIBRINOGEN RECEPTOR OCCUPANCY (FRO) AFTER ORAL TREATMENT WITH BIBU-104-XX IN HEALTHY-VOLUNTEERS, Thrombosis and haemostasis, 73(6), 1995, pp. 1315-1315
PHARMACODYNAMICS AND PHARMACOKINETICS OF BIBU-52, A PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG BIBU-104 IN MAN/
Authors: MULLER TH WEISENBERGER H BRICKL R KIRCHNER M NARJES H HIMMELSBACH F GUTH B KRAUSE J
Citation: Th. Muller et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF BIBU-52, A PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG BIBU-104 IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1445-1445
ANTI-AGGREGATORY PROFILE OF THE PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST BIBU-52 IN EX-VIVO STUDIES IN MAN/
Authors: MULLER TH WEISENBERGER H BRICKL R RUHR K NARJES H HIMMELSBACH F
Citation: Th. Muller et al., ANTI-AGGREGATORY PROFILE OF THE PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST BIBU-52 IN EX-VIVO STUDIES IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1447-1447
THE EFFECT OF MELOXICAM ON THE PHARMACOKINETICS OF BETA-ACETYL-DIGOXIN
Authors: DEGNER FL HEINZEL G NARJES H TURCK D
Citation: Fl. Degner et al., THE EFFECT OF MELOXICAM ON THE PHARMACOKINETICS OF BETA-ACETYL-DIGOXIN, British journal of clinical pharmacology, 40(5), 1995, pp. 486-488
THE EFFECT OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF MELOXICAM, A NEW NONSTEROIDAL ANTIINFLAMMATORY DRUG (NSAID), IN MAN
Authors: BUSCH U HEINZEL G NARJES H
Citation: U. Busch et al., THE EFFECT OF CHOLESTYRAMINE ON THE PHARMACOKINETICS OF MELOXICAM, A NEW NONSTEROIDAL ANTIINFLAMMATORY DRUG (NSAID), IN MAN, European Journal of Clinical Pharmacology, 48(3-4), 1995, pp. 269-272
PHARMACODYNAMICS OF DTTX-30-SE, A TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE (TX) SYNTHETASE INHIBITOR, AFTER MULTIPLE ORAL DOSING IN MAN/
Authors: NARJES H MULLER TH WEISENBERGER H TANSWELL P DEICHSEL G SU CAPF
Citation: H. Narjes et al., PHARMACODYNAMICS OF DTTX-30-SE, A TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE (TX) SYNTHETASE INHIBITOR, AFTER MULTIPLE ORAL DOSING IN MAN/, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 141-141
Risultati: 1-13 |